Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FWBZG
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,555
Award facts
- Contract value 100% obligated
- $7,554.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded July 18, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of RINVOQ ER 15 mg tablets in a 30-count unit dosage format. The contract represents a firm fixed-price delivery order with a ceiling value of $7,554.64 and an ultimate completion date of July 21, 2025. The award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026.
RINVOQ ER (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and other inflammatory conditions. As a pharmaceutical distributor serving federal military and veteran healthcare systems, AmerisourceBergen Drug Corp supplies medications and medical commodities across multiple therapeutic domains to support the Defense Health Agency and related government healthcare programs. The DLA Medical Supply Chain relies on prime vendors such as AmerisourceBergen to maintain consistent pharmaceutical availability for military personnel and beneficiaries worldwide. The three-day completion timeline reflects the expedited nature of this delivery order within the broader pharmaceutical support framework managed through the SPE2DX vehicle.
Quick answers
Who was awarded contract SPE2DB25FWBZG?
SPE2DB25FWBZG was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 18, 2025.
How much is contract SPE2DB25FWBZG worth?
The government has obligated $7,555 on SPE2DB25FWBZG.
Is contract SPE2DB25FWBZG an order under another contract?
Yes. SPE2DB25FWBZG is a delivery order under SPE2DB25D3022, an indefinite delivery contract.
Was contract SPE2DB25FWBZG competed?
The extent of competition for SPE2DB25FWBZG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award